Expert menopause and weight care, 100% online
Embirwell

Medical weight loss

Semaglutide Cost: What You Will Actually Pay

Semaglutide cost depends on the brand, dose, formulation, and payment route. A starter offer can be much lower than the continuing price. Ask for the cost at the dose you are likely to maintain, plus any separate appointment or membership charges.

Treatment packaging, a bottle, and an injection pen on a tabletop

Manufacturer self-pay prices vary by dose

US manufacturer offers checked October 6, 2026; eligibility and terms apply
ProductPublished monthly self-pay price
Wegovy tablets$149 at 1.5 mg; $199 at 4 mg; $299 at 9 mg and 25 mg.
Wegovy standard injection$349. Eligible new patients can pay $199 for two starting-dose fills through December 31, 2026.
Wegovy HD 7.2 mg injection$399.
Ozempic injection$349 at doses through 1 mg; $499 at 2 mg. Eligible new patients have a two-fill $199 starting-dose offer through December 31, 2026.
Ozempic tablets$149 at 1.5 mg; $199 at 4 mg; $299 at 9 mg.

These prices apply through the specified manufacturer channels, with offer terms and eligibility restrictions. The manufacturer can change or cancel them. A 'month' is defined by the supplied package, such as four Wegovy injection pens or thirty tablets. Confirm the current offer and the exact quantity before arranging payment.

Sources: 1, 2

A savings card does not guarantee a $25 bill

The current Wegovy and Ozempic commercial-insurance offers advertise payments as low as $25, with a maximum saving of $100 per month. Eligibility and restrictions apply, and government beneficiaries are excluded from that commercial copay offer. The saving cap means a high copay may remain high.

Ask the insurer whether the exact product is covered for your diagnosis, whether prior authorization is required, and what you owe before and after the deductible. Wegovy and Ozempic have different indications. Coverage for a diabetes brand does not establish coverage for weight treatment.

Manufacturer self-pay arrangements operate separately from insurance. NovoCare's Wegovy terms state that self-pay spending and discounts do not count toward the plan's deductible or out-of-pocket requirements and cannot be submitted for reimbursement. Compare both payment routes before choosing one.

Eligible Medicare Part D beneficiaries may have a separate route through the Medicare GLP-1 Bridge, operating July 1, 2026, through December 31, 2027. Medicare lists Wegovy injections and tablets among covered options with a $50 monthly copay. Specific BMI and clinical criteria, exclusions, and prior authorization apply. This program operates outside ordinary Part D payment flow and commercial savings offers.

Sources: 3, 2, 4, 5, 6, 7, 8

Request an itemized continuing-treatment quote

  • Medication brand, formulation, strength, package size, and dispensing pharmacy.
  • Price after the starting offer ends and after a dose increase.
  • Consultation, membership, shipping, and any required laboratory fees.
  • What follow-up is included and whether the fee continues during a medication interruption.
  • Cancellation, refund, and renewal terms.

For a practical budget, multiply the continuing package price by the number of fills you expect and add the separately charged care. Use the actual package duration. Four weekly doses cover twenty-eight days, which differs from a thirty-tablet supply or a calendar month.

Insurance approval may expire or require a renewal documenting response. Ask who handles that process and when it starts. A prescription that is clinically suitable can still need a separate coverage decision.

Sources: 1, 2, 4

Check the product behind a lower price

A low advertised 'semaglutide' price may refer to a compounded preparation or to a service fee that excludes medicine. FDA-approved brands and compounded products have different regulatory status. Compounded drugs are not FDA-approved and should be used only when an approved drug cannot meet a medical need.

Verify the pharmacy's license and ask for the exact ingredient and strength. FDA warns about semaglutide salts, fraudulent labeling, and dosing errors. Avoid research products sold with instructions for human use. If cost threatens continued treatment, discuss an approved alternative and an interruption plan with the clinician.

Sources: 9, 10, 11

Sources

References cited in this article.